Blood test may unlock faster POTS diagnosis

NCT ID NCT03218761

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to validate a blood test that measures NET mRNA levels as a simpler way to assess norepinephrine transporter function in people with Postural Tachycardia Syndrome (POTS). Researchers will compare these levels with traditional measures in 200 participants, including those with POTS and healthy controls. If the test works, it could make diagnosing POTS easier and faster.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a simpler blood test to help diagnose POTS, replacing older, more complex methods.

What could go wrong

This is an early validation study, not a treatment trial. The blood test may not correlate well with actual NET function, limiting its diagnostic value.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTURAL TACHYCARDIA SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

postural orthostatic tachycardia syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States